Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Nitenpyram

Detailed information about Nitenpyram

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the treatment of flea infestations.

What to watch for:

  • For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater
  • The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian
  • For use in cats and kittens 4 weeks of age and older
  • The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian
  • very low energy (1 reports)
  • Other abnormal test result NOS (1 reports)
  • Oral bleeding (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater
  • The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian
  • For use in cats and kittens 4 weeks of age and older
  • The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian
  • very low energy

Most reported reactions:

  • Tiredness (lethargy) (1 reports)
  • Other abnormal test result NOS (1 reports)
  • Oral bleeding (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:01 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 16, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Image coming soon
Nitenpyram

Nitenpyram

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Tablet
Identifiers:
NADA: 141175 NADA: 141204 NADA: 141205 NDC Package: 21091-141-01 NDC Package: 21091-141-05 NDC Package: 21091-142-01 NDC Package: 21091-142-05 NDC Package: 21091-175-01 NDC Package: 21091-175-03 NDC Package: 21091-175-04 NDC Package: 21091-175-05 NDC Package: 21091-178-01 NDC Package: 21091-178-03 NDC Package: 21091-178-04 NDC Package: 21091-178-05 NDC Package: 62157-725-01 NDC Package: 73309-146-01 NDC Package: 73309-146-02 NDC Product: 21091 NDC Product: 62157
Source metadata:

Warnings / Contraindications

For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.

  • High: For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
28
Species represented
2
Grouped by Body System
Digestive (5) · Drooling, Diarrhea, Decreased appetite Skin & allergy (2) · Facial swelling (possible allergy), Biting - pruritus Neurologic (2) · Tiredness (lethargy), Muscle tremor Behavior (1) · Anxiety Other (22) · Other abnormal test result NOS, Oral bleeding, Not himself/herself
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1

Species coverage: Cat (17) Dog (15)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Neurologic Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Skin & allergy Dog Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Skin & allergy Cat Serious - 1
Digestive Cat Serious - 1
Behavior Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (0)
  • No official label or package insert links yet.
SPL (3)
FOI (4)
  • ucm117260.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/685
  • ucm117258.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/684
  • ucm117654.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/722
  • ucm117656.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/723
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 16, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: CAPSTAR® Program® Flavor Tabs® and Capstar® Flea Management System™ Sentinel® Flavor Tabs® and Capstar® Flea Management System™
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat And Kitten, Dog, Dogs and puppies
Rx/OTC: OTC, RX
Form/route: Tablet • Oral
Applications: NADA 141-175 • NADA 141-204 • NADA 141-205
Documents: 4 (FOI: 4) • SPL: 3 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 24 • Cat 27 • View
Case summaries: 10 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Related conditions: Fleas (Flea Infestation)
Linked using: Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: B88.1
Tungiasis and other infestations

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Tiredness (lethargy) (1) Other abnormal test result NOS (1) Oral bleeding (1) Not himself/herself (1) Not eating (1) Not drinking (1) Increased heart rate (1) Hypersensitivity reaction (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141175 NADA: 141204 NADA: 141205 NDC Package: 21091-141-01 NDC Package: 21091-141-05 NDC Package: 21091-142-01 NDC Package: 21091-142-05 NDC Package: 21091-175-01 NDC Package: 21091-175-03 NDC Package: 21091-175-04 NDC Package: 21091-175-05 NDC Package: 21091-178-01 NDC Package: 21091-178-03 NDC Package: 21091-178-04 NDC Package: 21091-178-05 NDC Package: 62157-725-01 NDC Package: 73309-146-01 NDC Package: 73309-146-02 NDC Product: 21091 NDC Product: 62157 NDC Product: 73309
Package NDC Product NDC Form / Route Status
21091-141-01 21091 -
21091-141-05 21091 -
21091-142-01 21091 -
21091-142-05 21091 -
21091-175-01 21091 -
21091-175-03 21091 -
21091-175-04 21091 -
21091-175-05 21091 -
21091-178-01 21091 -
21091-178-03 21091 -
21091-178-04 21091 -
21091-178-05 21091 -
62157-725-01 62157 -
73309-146-01 73309 -
73309-146-02 73309 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • ucm117258.pdf • FOI summary • Official • May 17, 2021
    FDA FOI summary for application 141175
  • ucm117260.pdf • FOI summary • Official • May 17, 2021
    FDA FOI summary for application 141175
  • ucm117654.pdf • FOI summary • Official • Aug. 3, 2020
    FDA FOI summary for application 141204
  • ucm117656.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141205

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 7 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavo… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy (ectoparasite) - flea, Lack of efficacy (flea), Vomiting, Lethargy (see also Central nervous system depressi… (Official, 2026-02-12)
  • usage: For the treatment of flea infestations. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets is indicated to kill adul… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
CAPSTAR®
OTC
Nitenpyram
Tablet • Oral
Label highlights
Official documents
Sergeant’s Pet Care Products LLC NADA 141-175 Approved May 17, 2021
Sentinel® Flavor Tabs® and Capstar® Flea Management System™
RX
Lufenuron Milbemycin Oxime Nitenpyram
Tablet • Oral
Label highlights
Official documents
Intervet, Inc. NADA 141-204 Approved Aug 3, 2020
Program® Flavor Tabs® and Capstar® Flea Management System™
RX
Lufenuron Nitenpyram
Tablet • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-205 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, Excluding Under 2 Pounds • Dogs and puppies, excluding puppies under 4 weeks age • Cat And Kitten, Excluding Under 4 Weeks Of Age • Cat And Kitten, Excluding Under 2 Pounds Weight
Composition / specifications
Each tablet contains 11.4 or 57 milligrams of nitenpyram.
Cats (2 - 25 Lbs)
Indication
For the treatment of flea infestations.
Dosage
One 11.4 mg tablet given once as needed, up to once daily.
Limitations
For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater.
Dogs (25.1-125 Lbs)
Indication
For the treatment of flea infestations.
Dosage
One 57 mg tablet given once as needed, up to once daily.
Limitations
For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater.
Dogs (2-25 Lbs)
Indication
For the treatment of flea infestations.
Dosage
One 11.4 mg tablet given once as needed, up to once daily.
Limitations
For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater.

FDA page: Open in Animal Drugs @ FDA

Species: Dogs and puppies, excluding puppies under 4 weeks age
Composition / specifications
Flavored tablets containing: 2.3 milligrams milbemycin oxime and 46 milligrams lufenuron, 5.75 milligrams milbemycin oxime and 115 milligrams lufenuron, 11.5 milligrams milbemycin oxime and 230 milligrams lufenuron, or 23 milligrams milbemycin oxime and 460 milligrams lufenuron.
concurrent with
Tablet contains 11.4 or 57 milligrams nitenpyram.
Dogs
Indication
The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets is indicated to kill adult fleas and prevent flea eggs from hatching.
Dosage
0.5 milligram milbemycin oxime and 10 milligrams lufenuron per kilogram of body weight, once a month. used concurrently with One 11.4-mg tablet for dogs weighing less than 25 lb or one 57 mg tablet for dogs weighing more than 25 lbs, once or twice weekly.
Limitations
The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dogs and puppies, excluding puppies under 4 weeks age • Cat And Kitten, Excluding Under 4 Weeks Of Age
Composition / specifications
PROGRAM® Flavor Tabs : 45 mg, 90 mg, 204.9 mg and 409.8 mg lufenuron
CAPSTAR® Tablets: 11.4 mg and 57 mg nitenpyram
Cats
Indication
In cats and kittens, the concurrent use of PROGRAM® Flavor Tabs® and CAPSTAR® Tablets is indicated to kill adult fleas and prevent flea eggs from hatching. The effects of PROGRAM® Flavor Tabs®, which control flea populations, and CAP STAR® Tablets, which treat flea infestations, are combined to provide a FLEA MANAGEMENT SYSTEM™.
Dosage
Minimum of 30 mg lufenuron per kilogram (13.6 milligrams per pound ) of body weight, once a month. Concurrently with One 11.4-milligram tablet nitenpyram, once or twice weekly.
Limitations
For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.
Dogs
Indication
In dogs and puppies, the concurrent use of PROGRAM® Flavor Tabs® and CAPSTAR® Tablets is indicated to kill adult fleas and prevent flea eggs from hatching. The effects of PROGRAM® Flavor Tabs®, which prevent and control flea populations, and CAPSTAR® Tablets, which treat flea infestations, are combined to provide a FLEA MANAGEMENT SYSTEM™.
Dosage
Minimum of 10 mg lufenuron per kilogram (4.5 milligrams per pound ) of body weight, once a month. Concurrently with One 11.4-milligram tablet for dogs weighing less than 25 lb or one 57 mg tablet for dogs weighing more than 25 lbs, once or twice weekly.
Limitations
For use in dogs and puppies 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary

     1. The text in the “Indications” section is changed to include the words “kill adult fleas.” The section will now read: “CAPSTAR® Tablets kill adult fleas and are indicated for the treatment of flea infestations on dogs, puppies, cats and kittens 4 weeks of age and older and 2 pounds of body weight or greater.” This change makes the labeling more consistent with labeling for other approved products that kill adult fleas.
    2. There are some minor revisions to clarify the currently approved text in the package insert and the unit dose cartons.
    3. The package insert is revised to include reference to the concurrent use of PROGRAM® (lufenuron) Flavor Tabs® (NADA 141-035) to kill adult fleas and prevent flea eggs from hatching. The information supporting approval for this concurrent use is documented in NADA 141-205.
    4. The package insert is revised to refer the reader to a veterinarian for information about the concurrent use of SENTINEL® (milbemycin oxime/lufenuron) Flavor Tabs® (NADA 141-084), to kill adult fleas and prevent flea eggs from hatching. SENTINEL® Flavor Tabs® are a prescription product. The information supporting approval for this concurrent use is documented in NADA 141-204.
    5. The unit dose cartons are revised to refer to concurrent use with PROGRAM® (lufenuron) Flavor Tabs®.
    6. Each unit dose carton will contain an additional “FLEA MANAGEMENT SYSTEM” package insert that provides specific information for using CAPSTAR® Tablets with PROGRAM® (lufenuron) Flavor Tabs®.

  • Summary
    For the treatment of flea infestations on dogs, puppies, cats and kittens four weeks of age and 2 pounds of body weight or greater.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    For use in dogs 4 weeks and older to kill adult fleas and to prevent flea eggs from hatching.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    For use to kill adult fleas and to prevent flea eggs from hatching.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of flea infestations. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets is indicated to kill adult fleas and prevent flea eggs from hatching. In cats and kittens, the concurrent use of PROGRAM® Flavor Tabs® and CAPSTAR® Tablets is indicated to kill adult fleas and prevent flea eggs from hatching. The effects of PROGRAM® Flavor Tabs®, which control flea populations, and CAP STAR® Tablets, which treat flea infestations, are combined to provide a FLEA MANAGEMENT SYSTEM™.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Drooling (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Dog Blood in vomit (1) • Cat Appetite loss (1) • Cat

Showing top 5 for Digestive.

Skin & allergy
Facial swelling (possible allergy) (1) • Dog Biting - pruritus (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Tiredness (1) • Cat Muscle tremor (1) • Dog

Showing top 5 for Neurologic.

Behavior
Anxiety (1) • Cat

Showing top 5 for Behavior.

Other
Other abnormal test result NOS (1) • Dog Oral bleeding (1) • Cat Not himself/herself (1) • Dog Not eating (1) • Dog Not drinking (1) • Cat
Show more (17)
Increased heart rate (1) • Cat Hypersensitivity reaction (1) • Dog Hyperactivity (1) • Cat Hiding (1) • Dog Haemorrhage NOS (1) • Cat Gait abnormality (1) • Dog Gagging (1) • Dog Found dead (1) • Cat Food refusal (1) • Cat Fever (1) • Cat Elevated creatinine (1) • Cat Decreased drinking (1) • Dog Death (1) • Cat Dazed (1) • Dog Cardiac arrest (1) • Cat Allergic reaction (1) • Dog Administration error NOS (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Domestic Shorthair, Male, 6 month, 4.082 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per year • Reactions: Panting, Increased heart rate, Anxiety, Fever • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055702
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 6.00 Month
  • Weight: 4.082 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 tablet per dose
  • Frequency: 1 per year
Reactions Reported:
Panting Increased heart rate Anxiety Fever
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 8 year, 3.629 kilogram • Drug: MSK, Tablet, Oral, Dose: 11.40 Milligram per dose, Frequency: 1 per year • Reactions: Oral bleeding, Haemorrhage NOS, Food refusal, Cardiac arrest, Death… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055214
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 3.629 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 11.40 Milligram per dose
  • Frequency: 1 per year
Reactions Reported:
Oral bleeding Haemorrhage NOS Food refusal Cardiac arrest Death Vocalisation Increased heart rate
Outcomes: Died

Cat, Domestic Longhair, Female, 15 year, 3.175 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per year • Reactions: Found dead • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055212
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 15.00 Year
  • Weight: 3.175 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 tablet per dose
  • Frequency: 1 per year
Reactions Reported:
Found dead
Outcomes: Died

Dog, Dachshund (unspecified), Female, 9 year, 7.711 kilogram • Drug: MSK, Tablet, Oral, Dose: 11.40 Milligram per dose, Frequency: 1 per day • Reactions: Tremors, Tiredness (lethargy), Panting, Twitching, Systemic disorder NOS • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055213
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 7.711 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 11.40 Milligram per dose
  • Frequency: 1 per day
Reactions Reported:
Tremors Tiredness (lethargy) Panting Twitching Systemic disorder NOS
Outcomes: Recovered/Normal

Cat, Domestic Longhair, Male, 3 year, 5.443 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per day • Reactions: Tiredness (lethargy), Appetite loss, Blood in vomit, Not drinking, Vomiting… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-054642
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 3.00 Year
  • Weight: 5.443 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 tablet per dose
  • Frequency: 1 per day
Reactions Reported:
Tiredness (lethargy) Appetite loss Blood in vomit Not drinking Vomiting Hiding Administration error NOS
Outcomes: Ongoing

Dog, Shar Pei, Male, 8 month, 18.144 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per year • Reactions: Vomiting, Diarrhea, Decreased drinking, Not eating, Other abnormal test result NOS… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-054640
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 8.00 Month
  • Weight: 18.144 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 tablet per dose
  • Frequency: 1 per year
Reactions Reported:
Vomiting Diarrhea Decreased drinking Not eating Other abnormal test result NOS Not himself/herself
Outcomes: Ongoing

Cat, Russian, Male, 4 year, 6.804 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per day • Reactions: Vocalisation, Biting - pruritus, Fever, Hyperactivity, Tiredness (lethargy)… • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055701
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 4.00 Year
  • Weight: 6.804 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 tablet per dose
  • Frequency: 1 per day
Reactions Reported:
Vocalisation Biting - pruritus Fever Hyperactivity Tiredness (lethargy) Elevated creatinine Tachycardia
Outcomes: Recovered/Normal

Dog, Griffon - Brussels, Male, 5 year, 3.629 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per day • Reactions: Tiredness (lethargy), Dazed, Hiding, Gait abnormality, Vocalisation… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-053769
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 3.629 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 tablet per dose
  • Frequency: 1 per day
Reactions Reported:
Tiredness (lethargy) Dazed Hiding Gait abnormality Vocalisation Muscle tremor Not drinking
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.